Advertisement

Advertisement

HotelsFoodShoppingCoffeeGroceryGas

Kayaku Advanced Materials, Inc

Website

Advertisement

Advertisement

200 Flanders Rd
Westborough, MA 01581
https://kayakuam.com

Kayaku Advanced Materials, Inc is a leading provider of specialized materials and solutions for various industries. With a focus on innovation and quality, the company offers a range of advanced materials designed to meet the unique needs of its customers.

Located in Westborough, MA, Kayaku Advanced Materials, Inc is committed to delivering cutting-edge products and services that drive success and efficiency for businesses worldwide. Through continuous research and development, the company remains at the forefront of the materials industry.

Generated from their business information

Also at this address

Microchem Corp

Nippon Kayaku America Inc.

Dover Instrument Corp

Microchem Corp

Own this business?
Claim it
See a problem?

You might also like

Sizes

AssayQuant Technologies Inc.

AssayQuant Technologies Inc. is a leading life science company based in Marlborough, MA, dedicated to supporting the development of more effective therapies for serious conditions such as cancer, chronic inflammation, and neurodegeneration. With their proprietary PhosphoSens Technology, AssayQuant offers a powerful approach for understanding kinase and phosphatase function, enabling the identification of the most effective drugs. Their direct, real-time, kinetic, enzyme activity assays provide better data and enable faster movement through the drug discovery process. AssayQuant's catalog of over four hundred optimized assays, developed from curated libraries of fluorogenic peptide sensor substrates, allows for rapid ranking of candidates by inhibition mechanism, selectivity profiling, and potency measures. In addition to their catalog kits and bulk reagents, AssayQuant also provides assay development services and compound testing services. Committed to innovation, AssayQuant is driven by a shared vision of reducing suffering and building a healthier world.Generated from the website
Business services, nec, nec, Feathers and feather products, Drugs acting on the respiratory system

Sunovion

Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of pharmaceutical products directed toward serving unmet medical needs. The company s drug development program has yielded a portfolio of pharmaceutical compounds with a focus on respiratory and central nervous system disorders. Its commercialization efforts are carried out by a United States-based nearly 1,250-person primary care and specialty sales force through co-promotion agreements and through out-licensing partnerships. Sunovion Pharmaceuticals selects development compounds with the potential to offer improvements over existing therapies with respect to efficacy, side-effect profile, dosage forms and, in some cases, the opportunity for additional indications. The focus of its discovery effort is to identify additional drug candidates that are directed toward treating respiratory and central nervous system disorders. These compounds are expected to complement Sunovion Pharmaceuticals pharmaceutical pipeline. Sunovion Pharmaceuticals is headquartered n Marlborough, Mass.
Sizes, Building construction consultant, Drugs acting on the respiratory system

Alzheon, Inc

Alzheon, based in Framingham, MA, is a biotech company focused on developing a groundbreaking oral treatment for Alzheimer's disease. Their lead candidate, ALZ-801 valiltramiprosate, is currently in Phase 3 testing and is the only oral anti-amyloid disease-modifying treatment in development. With a precision medicine approach, Alzheon aims to slow or even stop disease progression, and potentially prevent the onset of clinical symptoms. Their research, spanning nine years, has resulted in a well-tolerated treatment with a favorable safety profile, making it a promising solution for Alzheimer's patients. Founded in 2013 by Martin Tolar, MD, PhD, Alzheon is dedicated to bringing ALZ-801 to market as the first oral disease-modifying treatment for Alzheimer's. The company has received significant funding, including $51 million in grants from the National Institute on Aging, to support their Phase 3 study. With a validated approach and a prominent global Scientific Advisory Board, Alzheon has published nine peer-reviewed scientific publications on key discoveries in Alzheimer's. Their focus on precision medicine and targeting high-risk patients with specific genetic markers demonstrates their commitment to finding a better solution for Alzheimer's disease.Generated from the website
United States›Massachusetts›Westborough›Kayaku Advanced Materials, Inc

Partial Data by Infogroup (c) 2024. All rights reserved.

Advertisement

Advertisement

  • Get directions
  • MapQuest Travel
  • Route Planner
  • Print your map
  • Get help
  • Search the web
  • Send feedback
Learn more about our mobile apps.
  • Android app Google Play
  • Download on the App Store
  • Download on the Amazon Appstore
  • Enterprise solutions
  • Claim your business
  • Developer resources
  • Jobs
  • Advertise with us
  • Terms of use
  • Privacy policy
  • Data and licenses
  • About our ads
  • Do not sell